SCHEMBL878174

SCHEMBL878174

COc1ccc2c(c1)c(CC(=O)NCCCCNC(C)=O)c(C)n2C=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 11/20 0.55
PTGS1 P23219 3/20 0.55
HRH4 Q9H3N8 2/20 0.54
HDAC3 O15379 3/20 0.52
HDAC1 Q13547 3/20 0.52
HDAC8 Q9BY41 3/20 0.52
HDAC6 Q9UBN7 3/20 0.52
HDAC2 Q92769 1/20 0.52
APP P05067 1/20 0.49
BCHE P06276 1/20 0.49
ACHE P22303 1/20 0.49
NQO2 P16083 2/20 0.49
MTNR1A P48039 2/20 0.49
MTNR1B P49286 2/20 0.49
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48
CA9 Q16790 1/20 0.48
PLA2G2A P14555 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13290332 0.92 PTGS2 (0.57) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL13290371 0.90 PTGS2 (0.54) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL13290395 0.88 PTGS2 (0.52) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL13290401 0.84 PTGS2 (0.49) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL13290452 0.83 AVPR1B (0.48) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL13290394 0.83 PTGS2 (0.49) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL13290387 0.79 HDAC4 (0.49) PTGS2PTGS1HRH4HDAC6
SCHEMBL861433 0.79 PTGS2 (0.86) PTGS2PTGS1HRH4HDAC3HDAC1
SCHEMBL10147894 0.79 KDM4E (0.53) PTGS2PTGS1HRH4MTNR1AMTNR1B
SCHEMBL878697 0.78 PTGS2 (0.59) PTGS2PTGS1HRH4HDAC3HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143302-B2 Methods and compositions for diagnostic and therapeutic targeting of COX-2 VANDERBILT UNIVERSITY (US) 2012-03-27 US disclosed
US-20100254910-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 VANDERBILT UNIVERSITY (US) 2010-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100254910-A1 METHODS AND COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC TARGETING OF COX-2 PTGS2, PTGES2, PTGER2 PTGS2 1/4885PTGS1 5/4885HRH4 2214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.